vs
ANI PHARMACEUTICALS INC（ANIP）とBristow Group Inc.（VTOL）の財務データ比較。上の社名をクリックして会社を切り替えられます
Bristow Group Inc.の直近四半期売上が大きい（$377.3M vs $247.1M、ANI PHARMACEUTICALS INCの約1.5倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 4.9%、差は6.2%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 6.7%）。Bristow Group Inc.の直近四半期フリーキャッシュフローが多い（$47.8M vs $29.1M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 5.8%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
ブリストウ・グループ傘下のブリストウ・ヘリコプターズ・リミテッドはイギリスの民間ヘリコプター運営企業で、当初はスコットランドのアバディーン空港を拠点としていました。現在は本社を米国テキサス州ヒューストンに置き、2020年に米国の大手民間ヘリコプター運営企業であるエラ・ヘリコプターズと合併し、合併後もブリストウの名称で事業を展開しています。
ANIP vs VTOL — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $377.3M |
| 純利益 | $27.5M | $18.4M |
| 粗利率 | — | — |
| 営業利益率 | 14.1% | 8.5% |
| 純利益率 | 11.1% | 4.9% |
| 売上前年比 | 29.6% | 6.7% |
| 純利益前年比 | 367.5% | -42.1% |
| EPS（希薄化後） | $1.14 | $0.61 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $377.3M | ||
| Q3 25 | $227.8M | $386.3M | ||
| Q2 25 | $211.4M | $376.4M | ||
| Q1 25 | $197.1M | $350.5M | ||
| Q4 24 | $190.6M | $353.5M | ||
| Q3 24 | $148.3M | $365.1M | ||
| Q2 24 | $138.0M | $359.7M | ||
| Q1 24 | $137.4M | $337.1M |
| Q4 25 | $27.5M | $18.4M | ||
| Q3 25 | $26.6M | $51.5M | ||
| Q2 25 | $8.5M | $31.7M | ||
| Q1 25 | $15.7M | $27.4M | ||
| Q4 24 | $-10.3M | $31.8M | ||
| Q3 24 | $-24.2M | $28.2M | ||
| Q2 24 | $-2.3M | $28.2M | ||
| Q1 24 | $18.2M | $6.6M |
| Q4 25 | 14.1% | 8.5% | ||
| Q3 25 | 15.9% | 13.1% | ||
| Q2 25 | 6.6% | 11.3% | ||
| Q1 25 | 13.3% | 9.6% | ||
| Q4 24 | -2.3% | 9.0% | ||
| Q3 24 | -13.8% | 9.1% | ||
| Q2 24 | 3.7% | 12.4% | ||
| Q1 24 | 14.8% | 6.8% |
| Q4 25 | 11.1% | 4.9% | ||
| Q3 25 | 11.7% | 13.3% | ||
| Q2 25 | 4.0% | 8.4% | ||
| Q1 25 | 8.0% | 7.8% | ||
| Q4 24 | -5.4% | 9.0% | ||
| Q3 24 | -16.3% | 7.7% | ||
| Q2 24 | -1.7% | 7.8% | ||
| Q1 24 | 13.2% | 2.0% |
| Q4 25 | $1.14 | $0.61 | ||
| Q3 25 | $1.13 | $1.72 | ||
| Q2 25 | $0.36 | $1.07 | ||
| Q1 25 | $0.69 | $0.92 | ||
| Q4 24 | $-0.45 | $1.07 | ||
| Q3 24 | $-1.27 | $0.95 | ||
| Q2 24 | $-0.14 | $0.96 | ||
| Q1 24 | $0.82 | $0.23 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $286.2M |
| 総負債低いほど良い | — | $671.5M |
| 株主資本純資産 | $540.7M | $1.1B |
| 総資産 | $1.4B | $2.3B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.63× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $286.2M | ||
| Q3 25 | $262.6M | $245.5M | ||
| Q2 25 | $217.8M | $251.8M | ||
| Q1 25 | $149.8M | $191.1M | ||
| Q4 24 | $144.9M | $247.5M | ||
| Q3 24 | $145.0M | $200.3M | ||
| Q2 24 | $240.1M | $178.6M | ||
| Q1 24 | $228.6M | $140.6M |
| Q4 25 | — | $671.5M | ||
| Q3 25 | — | $675.0M | ||
| Q2 25 | — | $705.2M | ||
| Q1 25 | — | $701.9M | ||
| Q4 24 | — | $689.8M | ||
| Q3 24 | — | $629.1M | ||
| Q2 24 | — | $594.2M | ||
| Q1 24 | — | $544.1M |
| Q4 25 | $540.7M | $1.1B | ||
| Q3 25 | $505.8M | $1.0B | ||
| Q2 25 | $436.8M | $984.4M | ||
| Q1 25 | $418.6M | $931.7M | ||
| Q4 24 | $403.7M | $891.7M | ||
| Q3 24 | $405.9M | $899.2M | ||
| Q2 24 | $455.8M | $849.1M | ||
| Q1 24 | $452.0M | $820.7M |
| Q4 25 | $1.4B | $2.3B | ||
| Q3 25 | $1.4B | $2.3B | ||
| Q2 25 | $1.3B | $2.3B | ||
| Q1 25 | $1.3B | $2.2B | ||
| Q4 24 | $1.3B | $2.1B | ||
| Q3 24 | $1.3B | $2.1B | ||
| Q2 24 | $920.8M | $2.0B | ||
| Q1 24 | $914.5M | $1.9B |
| Q4 25 | — | 0.63× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | 0.77× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.66× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $76.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $47.8M |
| FCFマージンFCF / 売上 | 11.8% | 12.7% |
| 設備投資強度設備投資 / 売上 | 0.5% | 7.7% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 4.17× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $56.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $76.9M | ||
| Q3 25 | $44.1M | $23.1M | ||
| Q2 25 | $75.8M | $99.0M | ||
| Q1 25 | $35.0M | $-603.0K | ||
| Q4 24 | $15.9M | $51.1M | ||
| Q3 24 | $12.5M | $66.0M | ||
| Q2 24 | $17.4M | $33.7M | ||
| Q1 24 | $18.3M | $26.7M |
| Q4 25 | $29.1M | $47.8M | ||
| Q3 25 | $38.0M | $-6.2M | ||
| Q2 25 | $71.8M | $67.4M | ||
| Q1 25 | $32.5M | $-52.7M | ||
| Q4 24 | $13.5M | $-32.4M | ||
| Q3 24 | $7.7M | $9.0M | ||
| Q2 24 | $13.0M | $-16.7M | ||
| Q1 24 | $13.7M | $-37.9M |
| Q4 25 | 11.8% | 12.7% | ||
| Q3 25 | 16.7% | -1.6% | ||
| Q2 25 | 34.0% | 17.9% | ||
| Q1 25 | 16.5% | -15.0% | ||
| Q4 24 | 7.1% | -9.2% | ||
| Q3 24 | 5.2% | 2.5% | ||
| Q2 24 | 9.4% | -4.6% | ||
| Q1 24 | 10.0% | -11.2% |
| Q4 25 | 0.5% | 7.7% | ||
| Q3 25 | 2.7% | 7.6% | ||
| Q2 25 | 1.9% | 8.4% | ||
| Q1 25 | 1.3% | 14.9% | ||
| Q4 24 | 1.3% | 23.6% | ||
| Q3 24 | 3.2% | 15.6% | ||
| Q2 24 | 3.2% | 14.0% | ||
| Q1 24 | 3.3% | 19.2% |
| Q4 25 | 1.10× | 4.17× | ||
| Q3 25 | 1.66× | 0.45× | ||
| Q2 25 | 8.87× | 3.12× | ||
| Q1 25 | 2.23× | -0.02× | ||
| Q4 24 | — | 1.61× | ||
| Q3 24 | — | 2.34× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | 1.00× | 4.04× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
VTOL
| Offshore Energy Services | $247.5M | 66% |
| Government Services | $100.1M | 27% |
| Other | $21.9M | 6% |
| Related Party | $7.8M | 2% |
